Guardant Health (NASDAQ:GH) Director Musa Tariq Sells 116 Shares

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $130.19, for a total value of $15,102.04. Following the completion of the sale, the director directly owned 8,796 shares in the company, valued at approximately $1,145,151.24. The trade was a 1.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Monday, May 18th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $95.96, for a total value of $11,131.36.
• On Thursday, April 16th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $84.83, for a total value of $9,840.28.
• On Wednesday, March 18th, Musa Tariq sold 348 shares of Guardant Health stock. The shares were sold at an average price of $88.09, for a total value of $30,655.32.

Guardant Health Stock Performance

GH stock traded down $2.48 on Tuesday, reaching $127.34. The company had a trading volume of 2,672,243 shares, compared to its average volume of 2,126,646. Guardant Health, Inc. has a 1 year low of $40.35 and a 1 year high of $135.00. The company’s fifty day moving average is $104.23 and its 200 day moving average is $102.22. The company has a market cap of $16.89 billion, a P/E ratio of -37.56 and a beta of 1.61.

Analyst Ratings Changes

A number of brokerages have recently commented on GH. Citigroup lifted their price target on shares of Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Stifel Nicolaus lifted their price target on shares of Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 20th. The Goldman Sachs Group began coverage on shares of Guardant Health in a report on Friday, June 5th. They set a “buy” rating and a $165.00 price target for the company. Robert W. Baird began coverage on Guardant Health in a report on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 price target for the company. Finally, Canaccord Genuity Group boosted their price target on Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, February 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $141.95.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Allworth Financial LP raised its holdings in Guardant Health by 19.5% in the 3rd quarter. Allworth Financial LP now owns 844 shares of the company’s stock valued at $53,000 after acquiring an additional 138 shares during the last quarter. Eastern Bank raised its holdings in Guardant Health by 6.9% in the 4th quarter. Eastern Bank now owns 2,160 shares of the company’s stock valued at $221,000 after acquiring an additional 139 shares during the last quarter. First Pacific Financial raised its holdings in Guardant Health by 33.1% in the 1st quarter. First Pacific Financial now owns 559 shares of the company’s stock valued at $52,000 after acquiring an additional 139 shares during the last quarter. Xponance LLC raised its holdings in Guardant Health by 2.1% in the 4th quarter. Xponance LLC now owns 9,630 shares of the company’s stock valued at $984,000 after acquiring an additional 199 shares during the last quarter. Finally, Danske Bank A S raised its holdings in Guardant Health by 20.0% in the 4th quarter. Danske Bank A S now owns 1,200 shares of the company’s stock valued at $123,000 after acquiring an additional 200 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.